Plain-English translation of NCT07461441 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing faricimab, a new medication given as regular eye injections, to treat polypoidal choroidal vasculopathy (PCV)—a serious eye disease where abnormal blood vessels leak fluid under the retina and cause vision loss. The study uses a personalized approach: your doctor will start with injections every 8 weeks, then adjust the schedule based on how your eye responds, spacing them out longer if you're doing well or giving them more frequently if needed.
Many people with this condition lose vision because current treatments don't work well enough or require frequent, inconvenient visits. This trial is testing whether this new medication, given on a flexible schedule tailored to each person, can better control the disease and reduce how often you need to come in for injections.
You likely qualify if…
You likely don't qualify if…
You will receive loading injections of the medication into your eye, then enter a personalized treatment schedule starting with injections every 8 weeks. At each visit, your eye will be imaged to check for fluid or other signs of disease activity. If your eye is stable, the time between injections may be extended up to 24 weeks; if disease activity is detected, injections will be given more frequently. The study lasts at least 12 months, with regular monitoring visits to track your vision and eye health.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
South Korea